Thermo Fisher has established four core business segments: life science solutions (such as gene sequencers and PCR equipment), professional diagnostics (including COVID-19 testing reagents), laboratory products and services (consumables and cloud platforms), and analytical instruments (mass spectrometry and electron microscopy). The company continues to expand its technological boundaries through strategic acquisitions such as Life Technologies and Patheon, with over 5000 patents and serving clients including research institutes, hospitals, and pharmaceutical giants such as Johnson&Johnson and Pfizer. Its iconic products such as Ion GeneStudio sequencer and Orbitrap mass spectrometer have become industry standards.

In 2023, Thermo Fisher's annual revenue will exceed $45 billion, with significant growth in mRNA therapy, cell and gene therapy (CGT). Recently, the focus has been on AI driven laboratory automation (such as the AutoScheduler intelligent scheduling system) and sustainable solutions (such as the Green Laboratory Program). The company plans to invest $2 billion over the next five years to expand into the Asia Pacific market and accelerate precision medicine and biopharmaceutical CDMO services, consolidating its global leadership position as the "Amazon of Science Services".